Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

8 novembre 2017

07:00
Building upon publication of clinical trial results in Nature, PNAS, Lancet Infectious Diseases, and JCI Insight in 2017, Sanaria Inc. is highlighting the work of its many collaborators at a symposium entitled "Moving Toward a PfSPZ Malaria Vaccine...

04:16
First pilot of a new cancer care model which leverages the role of the pharmacist by the Vanguard New Models of Care Programme   Programme will improve cancer patient care across a catchment population of 3.5 million people   New care model may be...

03:50
Cantargia AB's ("Cantargia") interim report for the third quarter of 2017 is now available on the company's web page www.cantargia.com/en/investors/financial-reports. Significant events in the third quarter  In July, Cantargia received approval to...

03:03
Nordic Nanovector ASA (OSE: NANO) notes that information relating to an application for a Protocol Amendment to the LYMRIT 37-01 study, for the planned pivotal Phase 2b clinical trial PARADIGME to evaluate Betalutin® (177Lu-lilotomab satetraxetan) in...


7 novembre 2017

17:03
OncoSec Medical Incorporated ("OncoSec" or "Company") , a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Daniel J. O'Connor as CEO of the Company.  His appointment is effective immediately. ...

17:00
Considered a safe and highly effective contraception method, intrauterine devices (IUDs) may also be quietly offering protection against the third-most common cancer in women worldwide. A new study from the Keck School of Medicine of USC has found...

16:20
SCYNEXIS, Inc. , a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended September 30, 2017, and provided an update on...

16:01
Arena Pharmaceuticals, Inc. , today provided a corporate update and reported financial results for the third quarter ended September 30, 2017. "We are pleased with the progress we achieved during the third quarter, hitting multiple milestones for...

14:05
FOR MEDICAL AND TRADE MEDIA ONLY                                  60% of patients receiving ustekinumab showed significant reductions in lupus disease activity vs. 31% of patients receiving placebo     Ustekinumab showed...

14:04
FOR MEDICAL AND TRADE MEDIA ONLY  Longer-term results demonstrate continued efficacy of anti-interleukin 23 monoclonal antibody guselkumab in improving joint and skin symptoms associated with active psoriatic arthritis   Janssen Research &...

13:49
Boston Children's Hospital today announced a $350,000 commitment to support malaria research and the music therapy program for children in honor of Dr. Gary Loveman. The gift includes a $250,000 contribution from the Caesars Entertainment Corporation...

12:00
GSK today announced results from BLISS-SC, a 52-week study for BENLYSTA (belimumab) for subcutaneous use (SC) in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving Standard of Care (SoC). The data...

10:17
LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced topline interim results from the LIGHTSITE I trial for treatment of dry...

09:30
Le Centre de recherche sur le vieillissement (CDRV) du CIUSSS de l'Estrie - CHUS vient d'être désigné officiellement comme centre collaborateur OPS/OMS des villes et communautés amies des aînés. Cette désignation est attribuée à l'équipe de recherche...

09:00
Novoclem Therapeutics, Inc., today announced that its lead inhaled antimicrobial drug candidate, BIOC51, has been designated as a "Qualified Infectious Disease Product" (QIDP) by the U.S. Food & Drug Administration.  The QIDP designation, granted for...

08:30
PharmaMar (MCE: PHM) has announced today a licensing agreement with Boryung Pharm to commercialize the marine-derived anticancer drug Zepsyre® (lurbinectedin), if approved, in South Korea. Under the terms of the agreement, PharmaMar receives a...

08:15
Alligator Bioscience , a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today results from a clinical phase I first-in-human study of the drug candidate ADC-1013 (JNJ-64457107), a human,...

08:10
Nektar Therapeutics today announced that new clinical data will be presented for NKTR-214, Nektar's lead immuno-oncology candidate, a CD122-biased agonist, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting at the Gaylord National...

08:02
Novartis announced today results from the FUTURE 5 study showing Cosentyx® (secukinumab) reduced the signs and symptoms of psoriatic arthritis (PsA) while significantly inhibiting the progression of joint structural damage in PsA patients compared to...

08:01
Infinity Pharmaceuticals, Inc. today announced its third quarter 2017 financial results and provided an update on the company, including its progress with IPI-549, an oral immuno-oncology product candidate that selectively inhibits...

08:00
Regeneron Pharmaceuticals, Inc. and Sanofi today announced new data analyses from the Praluent® (alirocumab) Injection ODYSSEY clinical trial program will be presented at the American Heart Association (AHA) Scientific Sessions 2017, November 11-15,...

08:00
Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that international data on Mino Loktm was recently presented at the ID...

08:00
Nektar Therapeutics  today announced it is presenting preclinical data on NKTR-358, a potential first-in-class resolution therapeutic that may address the underlying immune system imbalance in patients with many immune conditions, at the...

08:00
Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the presentation of scientific data supporting the selection of tumor types for Lycera's ongoing Phase 1/2a ARGON study of...

08:00
Janssen Research & Development, LLC (Janssen) announced today longer-term results from a Phase 2 study investigating TREMFYA® (guselkumab), the first selective anti-interleukin (IL)-23 monoclonal antibody to show positive results in the treatment of...

08:00
The U.S. Dept. of Defense is supporting SiteOne Therapeutics in the effort to develop the company's proprietary, highly selective small molecule Na?1.7 inhibitors for the treatment of acute and chronic pain.  In an...

08:00
Pique Therapeutics, Inc. today announced positive results for PT 107 from its Phase 2 clinical trial in patients with late-stage, second-line non-small cell lung cancer (NSCLC).  These results will be presented at the Society for the Immunotherapy of...

07:00
Galmed Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, today announced that its senior...

07:00
Reproductive Medicine Associates of New York (RMA of NY, www.rmany.com), one of the premier fertility centers in Manhattan, revealed modifiable lifestyle factors to be discussed prior to and after an infertile patient's initial reproductive care...

06:48
ArcherDX announced today that it has signed an agreement to develop and commercialize a next-generation sequencing (NGS)-based oncology companion diagnostic (CDx) for Celgene's investigational drug CC-122 for indications in Diffuse Large B Cell...

06:30
Ardelyx, Inc. , today provided an update on its clinical programs and reported financial results for the third quarter ended September 30, 2017. "2017 has been a landmark year for Ardelyx, with three statistically...

06:19
Aujourd'hui, Natera, Inc., , un leader mondial des tests ADN sans cellule, a annoncé une deuxième collaboration de recherche avec l'Université d'Aarhus au Danemark, faisant appel à sa technologie Signateratm (RUO) afin d'évaluer l'ADN tumoral...

06:12
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company and its collaborators present the key data of the Phase 2 study of TPX-100 in subjects with knee osteoarthritis (OA) as a late breaking abstract at...

05:05
New preclinical research suggests the potential utility of BPN14770, a selective PDE4D inhibitor currently under development by Tetra Discovery Partners as a prospective treatment for memory and cognitive problems associated with Alzheimer's disease,...

04:44
FOR MEDICAL AND TRADE MEDIA ONLY                                  60% of patients receiving ustekinumab showed significant reductions in lupus disease activity vs. 31% of patients receiving placebo     Ustekinumab showed...

04:00
Appointment of Tim Davis will help the company enhance its Reportum® service and drive its commercial growth MyMeds&Me, the leading SaaS provider of adverse event and product quality complaint solutions, has appointed experienced healthtech and...

04:00
Un nouveau livre blanc de la division Consumer Health de Merck met en lumière la nécessité de préparer la jeune génération pour vivre en bonne santé jusqu'à 100 ans   Le livre blanc met en avant l'importance d'adopter des habitudes saines très...

04:00
New whitepaper from Consumer Health business shines light on preparing the young generation for living 100 healthy years  Whitepaper focuses on the importance to adopt good health habits early on to prevent chronic conditions later in...

04:00
'Vaccination apathy' is a key barrier to protecting the community against infectious disease, according to global health experts   By 2060, 30% of Europeans will be aged 65 years or over[1] - a life-course approach to immunisation, including adult...


6 novembre 2017

17:04
CryoLife, Inc. , a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that enrollment has started in the Company's BioGlue clinical trial in China.  The results from the trial will serve as...

16:05
Ionis Pharmaceuticals, Inc. announced today that the company submitted a new drug application (NDA) to the U.S. Food and Drug Administration for inotersen, an investigational medicine for the treatment of patients with hereditary TTR amyloidosis...

16:01
CTI BioPharma Corp. today reported financial results for the third quarter ended September 30, 2017. Recent Highlights    Clinical / Regulatory In July 2017, the first patient was enrolled in PAC203, a Phase 2 clinical trial of pacritinib in...

12:12
Lynne Austin found she was increasingly out of breath doing even the simplest of tasks as 2015 came to a close. She couldn't walk more than a few steps at a time. She couldn't breathe. Her health was rapidly...

11:00
Findings from a new multi-country GSK survey, released today to coincide with the 2017 American College of Rheumatology/Association for Rheumatology Health Professionals Annual Meeting (ACR/AHRP), reveal that patients with systemic lupus...

10:55
Researchers from the Banner Alzheimer's Institute (BAI), Novartis, and Amgen today announced another step forward in the international effort to prevent Alzheimer's disease. The new study, known as the Alzheimer's Prevention Initiative (API)...

10:00
Takeda Pharmaceuticals U.S.A., Inc. (Takeda), Lundbeck U.S. and Advocate Health Care today announced a collaboration focusing on the use of digital technology to support people living with depression. "Patient Management of Depression through...

09:15
Lupus Research Alliance welcomes compelling new data, presented at the American College of Rheumatology (ACR) annual meeting that demonstrated significant benefit for lupus patients treated with Stelara® (ustekinumab), a prescription medicine from...

09:00
Amgen today announced new analyses will be presented from the Repatha® (evolocumab) cardiovascular outcomes study, including analyses investigating the efficacy of Repatha in high-risk patients with peripheral artery disease (PAD) and those who have...

09:00
Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced the initiation of MMPOWER-3, a Phase 3 study evaluating the efficacy and safety of daily...

09:00
Debiopharm International SA (Debiopharm - http://www.debiopharm.com), part of Debiopharm Grouptm, a Swiss-based global biopharmaceutical company, today announced the dosing of the first patient in a Phase Ib study of Debio 1143, an oral, small...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19